For a fast-growing biotech company with recently approved products in the US, Europe, and Japan, expanding into multiple markets was an exciting milestone...

For a biotech company with an established commercial product in the United States, expanding into Europe represented an important next step in its growth...

For a late-stage biotech company running nearly 10 clinical trials while preparing for its first commercial launch, supply planning had become increasingly difficult..

Apellis Pharmaceuticals was at a pivotal stage of growth, transitioning from managing a single commercial product to a multiproduct portfolio...